Testing luspatercept for transfusion-dependent non-severe aplastic anemia
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests if a drug called luspatercept can help people with a type of aplastic anemia that requires regular blood transfusions. It may reduce how often you need transfusions by boosting your body's own blood cell production.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older with non-severe aplastic anemia that depends on blood transfusions.
- A bone marrow test must show your body is trying to make red blood cells (more than 15% red cell precursors).
- If you've been on other treatments like immunosuppressants, androgens, or erythropoietin for at least 3–6 months, they must not have worked.
- You need a serum ferritin level of 1000 or higher, which shows iron overload from transfusions.
- You must agree to genetic testing (whole exome and MDS/AA panel).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four medicines (cyclosporine, eltrombopag or hetrombopag, romiplostim, and supportive care) for newly diagnosed aplastic anemia—a serious blood disorder where the bone marrow stops making enough blood cells. The goal is to help your bone marrow work better and reduce your need for blood transfusions.
This trial tests if luspatercept can help improve red blood cell counts in people with a certain type of acute myeloid leukemia (AML) who have mild to moderate anemia after intensive chemotherapy. It is for patients with a lower-risk form of AML who have completed 1–3 cycles of high-dose consolidation therapy.
This study tests a drug called luspatercept to see if it can help people who have low red blood cells (anemia) after a stem cell transplant for leukemia. It may improve your energy and reduce the need for blood transfusions.
This trial tests whether luspatercept can help improve low red blood cell counts (anemia) that happens soon after a stem cell transplant. It is for people with blood cancers who have very low hemoglobin after transplant.
This trial is testing whether a combination of two drugs, luspatercept and darbepoetin alfa, can help people with lower-risk myelodysplastic syndromes (MDS) who need frequent red blood cell transfusions. The goal is to see if the combination reduces their need for transfusions.
This trial tests whether a drug called luspatercept can help your body produce red blood cells better after a bone marrow transplant for blood cancer. The goal is to reduce complications and improve recovery.
Hear when a new Transfusion-dependent Non-severe Aplastic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.